EZH2 and cancer: Accordingly, reactivation of SLFN11 expression by epigenetic drugs targeting DNA methylation, histone deacetylase (HDAC), and histone methyltransferase EZH2 (Enhancer of zeste homolog 2) can reverse the chemoresistance of cancer cell lines that do not express SLFN11 (Figure 6A) [121,125,127].